Physician profile
Smita V Patel
NPI 1518180512
$1,473.51
in general payments reported to CMS, 2019-2025
21 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2021: $48.26 · 2022: $194 · 2023: $254 · 2024: $360 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.27 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.02 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $108.51 | 2019 | |
| Lilly USA, LLC | $88.96 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.35 | 2019-2025 | Jardiance |
| Abbott Laboratories | $84.31 | 2022-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $71.61 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $69.33 | 2019-2025 | Trelegy Ellipta |
| Recordati_rare_diseases_inc. | $67.84 | 2023-2024 | Isturisa, Signifor Lar |
| Amgen INC. | $48.27 | 2019 | |
| Urogen Pharma, INC. | $46.69 | 2025 | |
| Novo Nordisk INC | $39.47 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $29.73 | 2024-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $29.64 | 2025 | Inspire |
| Medtronic, INC. | $26.55 | 2024 | Inpen Smart Insulin Delivery System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $19.24 | 2023 | Omnipod |
| Dexcom, INC. | $19.15 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2023 | |
| Genentech USA, INC. | $18.40 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.53 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.